Drug intelligence / Profile preview

Yili Shutang formula

Development stage: Preclinical
Lead developer: Yili Group
Administration: Oral

Overview

Yili Shutang formula is a nutritional formula developed by Inner Mongolia Yili Industrial Group Co., Ltd. Jinshan Branch and General Hospital of the Chinese people's Liberation Army. It is designed to stabilize blood glucose, primarily for individuals with Type 2 diabetes. The formula is currently undergoing clinical studies to evaluate its efficacy and safety in this indication.

Other names: 伊利纾糖配方奶粉

Beyond the preview

Go deeper on Yili Shutang formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yili Shutang formula.

Explore the full profile